SkinBioTherapeutics (LSE:SBTX) has launched the initial phase of its AxisBiotix™ supplement range in collaboration with UK health and beauty retailer Superdrug. Designed to support skin health and reduce inflammation, AxisBiotix™ will first be available in select Superdrug stores with high sales of medicated skincare products, with a nationwide rollout scheduled for Spring 2026. This exclusive two-year partnership marks SkinBioTherapeutics’ first national high street presence, representing a key milestone in expanding the company’s market reach and product accessibility.
Despite this strategic move, SkinBioTherapeutics continues to face financial challenges, including ongoing losses and cash burn, which weigh heavily on the stock’s outlook. Technical indicators remain bearish, although recent corporate developments and partnerships provide potential upside if they translate into stronger financial performance.
About SkinBioTherapeutics
SkinBioTherapeutics is a life sciences company focused on skin health, leveraging its proprietary SkinBiotix® platform developed by the University of Manchester’s translational dermatology team. The company addresses the skin healthcare market through multiple product pillars, including cosmetic skincare and dietary supplements such as AxisBiotix-Ps™, targeting inflammatory skin conditions. SkinBioTherapeutics is expanding via strategic acquisitions and partnerships, including collaboration with Croda plc, and has been listed on AIM since April 2017, operating from Newcastle, UK.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply